Here, We used T-cell receptor transgenic mice specific for CD4+ T cell epitopes LCMV-GP 66-77 (SMARTA mice) and OVA 323–339 (OT-II mice) as models to study tumor-specific CD4+ T cells during cancer immunotherapy. This evidence concerns the gene CD4 and neoplasm.